suMMARY Treatment with vasodilators in heart failure has not always produced a useful improvement in the haemodynamic responses to exercise, and in many cases early drug tolerance has further limited the potential of this type of treatment. In a study to evaluate the efficacy of felodipine, a new calcium antagonist with selective vasodilator properties, in the management of congestive heart failure 10 patients with congestive heart failure underwent treadmill exercise testing before and during oral treatment with felodipine 30 mg daily. At every level of exercise felodipine lowered the pulmonary capillary wedge pressure, whereas cardiac index and stroke index increased considerably. The haemodynamic improvement was associated with an increase in the duration of exercise to exhaustion. Importantly, these beneficial effects were sustained throughout four weeks of treatment without evidence of drug tolerance. These observations suggest a useful role for felodipine in the long term management of congestive heart failure.
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In patients with chronic congestive heart failure exercise related fatigue and dyspnoea are the commonest and most troublesome symptoms. The reduced capacity of the failing heart to increase output to meet the metabolic demands of working muscle and the exagerated rise in left atrial pressure largely account for these symptoms. A critical evaluation of specific antifailure treatment must, therefore, examine the influence it has on the haemodynamic responses to exercise. An additional consideration is the long term efficacy of treatment. This is more difficult to assess since the natural history of congestive heart failure involves a variably progressive deterioration CAD  III  13  40  2  53M  CAD  III  27  500  3  63M  CAD  II  33  40*  4  38M  CAD  III  10  240  5  56F  CCM  III  23  80  6  66M  CAD  II  29 (4) 29 (1) 139 (8) 81 ( (1) 17 (4) 15 (1) 164 (12) 77 (5) Felodipine (day 3) 109 (4) 5 4 (04)** 49 (4)*** 9 (3)* 9 (1)*** 137 (5)*** 58 (2)*** Felodipine (day 28) 111 (3) 4-9 (0-2)** 44 (2)*** 6 (2)*** 9 (1)*** 135 (8)*** 59 (3)*** Placebo (day 30) 115 (2) 3-8 (0.1) 33 (1) 10 (2)*** 14 (1) 147 (8)*** 73 (4)* ibmaximal exercise
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28 (2) 16 (4) 19 (2) 166 (12) 82 ( Heart rate was monitored from a precordial lead. Arterial blood pressure was recorded from a cannula placed in the radial artery. A balloon tipped thermodilution catheter placed in the pulmonary artery was used to monitor pulmonary capillary wedge pressure and cardiac output (measured in duplicate using 10 ml of iced saline). All pressures were measured in the upright posture with reference to the mid-chest. Arterial and mixed venous samples for gas analysis were drawn, from the radial artery and the pulmonary artery respectively within one niinute of the cardiac output measurements. Blood oxygen content, arteriovenous oxygen difference, systemic oxygen consumption index, and derived haemodynamic variables were calculated using standard formulas. All patients were exercised on a treadmill. The Bruce protocol was used in eight patients and the less demanding Naughton protocol in two, both of whom had severely reduced exercise capacity. The same Exercise time (minutes) 7-2 (0 5) 9-0 (0-2)*** 8-9 (0-3)*** 8-8 (0.3)*** Plasma felodipine concentration (nmol/l) ND 35.1 (9-8) 35-6 (6-2) 5-8 (0.9)
Significance (p) of changes in exercise time with respect to control: ***<0-001.
ND, not detectable.
changed significantly (p<O-O5) were then subjected to a modified analysis using the Bonferonni method to identify the source of the differences.9
Results Table 2 summarises the haemodynamic responses to treadmill exercise before, during, and after long term treatment with felodipine. Figure 1 shows the effects Felodipine during exercise in heart failure 317 and stroke volume index (20(1) ml/beat/per m2), however, both showed pronounced reductions below the normal range. The mean duration of exercise to exhaustion was 7.2(0.5) minutes (Table 3) . During exercise, pulmonary capillary wedge pressure rose steeply to 26(5) mm Hg at peak exercise, whereas cardiac index and stroke volume index rose to only 5-2 (0.5) 1/min/per m2 and 37(3) ml/beat/per m2 respectively (Fig. 2) . Considerable increments in arteriovenous oxygen difference and systemic oxygen consumption index were also noted.
FELODIPINE TREATM.ENT (DAYS 3 AND 28).
Felodipine treatment produced a rapid improvement in both resting and exercise haemodynamics, which was sustained throughout the four week treatment period. The mean duration of exercise increased by 24% ( Table 3 ). The pulmonary capillary wedge pressure was lower at rest and at every level of exercise and never exceeded 16 (4) mm Hg. Cardiac index and stroke volume index also improved considerably during this period rising to 6.7(0.6) 1/min/per M2 and 48 (4) ml/beat/per m2 respectively at maximal exercise. Blood pressure at rest and during exercise and systemic vascular resistance were also significantly reduced but heart rate was unaffected by felodipine treatment (Fig. 2) . These beneficial haemodynamic effects were associated with a pronounced decline in the arteriovenous oxygen difference, although systemic oxygen consumption index remained unchanged (Fig. 1) . Plasma felodipine concentrations on days 3 and 28 of the study were similar (Table 3) . PLACEBO (DAY 30) Two days after felodipine withdrawal plasma concentration had fallen to 5.8(0 9) nmol/l, and a pronounced deterioration in the rest and exercise haemodynamic variables was seen. Cardiac index and stroke volume index fell considerably and were not significantly different from the control values. Nevertheless, despite an increase in the pulmonary capillary wedge pressure above the treatment levels it remained significantly lower than control values during exercise (Fig. 2) . The mean duration of exercise to exhaustion remained close to the level achieved during felodipine treatment ( Timmis, Smyth, Kenny, Campbell, Jewitt Discussion These data show that felodipine treatment in congestive heart failure is well tolerated and improves the haemodynamic responses to treadmill exercise. The haemodynamic improvement is associated with an increase in exercise tolerance. Importantly, both effects are sustained-during four weeks' treatment without evidence of tachyphylaxis.
Several short term clinical studies have shown that the vasodilator properties of calcium antagonists can improve left ventricular function in patients with congestive heart failure.'0-12 Enthusiasm for this approach, however, has been tempered by reports of pulmonary oedema and circulatory collapse during treatment with these compounds'l3-5 due presumably to an adverse effect on myocardial contractility. 16 17 For this reason calcium antagonists are not at present widely used in heart failure. Nevertheless, the recent introduction of felodipine, a nifedipine analogue with pronounced vascular selectivity, promises to extend the clinical application of this class of agents. Experimental work has shown that felodipine is a potent vasodilator with negligible effects on the myocardium.56 Short term clinical studies confirm that the drug is without detectable negative inotropic properties. 8 18 This distinguishes felodipine from other currently available calcium antagonists and suggests that the drug might be used safely in patients with congestive heart failure. The data we have presented support this suggestion.
The patients included in this study all had severe left ventricular dysfunction. Adequate diuretic treatment ensured that the resting pulmonary capillary wedge pressure in the upright posture was normal, although cardiac output was considerably reduced. The responses to treadmill exercise were typical for patients of this type.'9 20 An attenuated increase in cardiac output was seen despite a rapid and exaggerated rise in pulmonary capillary wedge pressure. Exercise capacity, therefore, was reduced because of the early onset of fatigue and dyspnoea. The vasodilator properties of felodipine lowered blood pressure and systemic vascular resistance at rest and produced a substantial increase in cardiac output.
Heart rate was unaffected indicating that the improvement in cardiac output was due entirely to an increase in stroke volume. The improvement in stroke volume will itself have tended to reduce the pulmonary capillary wedge pressure.21 Our Felodipine during exercise in heart failure index was higher with felodipine. Consequently, exercise capacity increased considerably. That the haemodynamic improvement was a direct result of the drug intervention is confirmed by the fact that felodipine withdrawal led to a sharp reduction in plasma concentrations associated with a rapid deterioration in left ventricular function towards the baseline level.
Previous investigations of vasodilator treatment in congestive heart failure have shown a similar improvement in cardiac output at submaiximal exercise, but reductions in left ventricular filling pressure usually occur only with drugs such as nitrates and prazosin, which have venodilator activity.23-25 Importantly, however, these studies have not always been able to show improvement in these haemodynamic variables at maximal exercise.2627 In this respect, therefore, felodipine appears to have advantage over some of the currently available vasodilators since useful effects on both the filling pressure and the output of the left ventricle were seen both at submaximal and at maximal exercise.
In the present study a four week treatment period was used to evaluate the long term efficacy of felodipine. Although relatively short, this period was chosen in order to minimise the confounding influence of deteriorating left ventricular function on the data interpretation. The findings show that both the plasma concentrations and the beneficial haemodynamic effects of felodipine are sustained, and tolerance to the drug does not occur. This represents an additional advantage of felodipine since early tachyphylaxis has been reported with several other vasodilators used for the treatment of heart failure.2-4 Prazosin, in particular, is subject to tolerance within the first several doses,34 although the clinical significance of this phenomenon remains uncertain and recent studies have been able to demonstrate long term efficacy.28 29 The increase in exercise cardiac output produced by felodipine was reflected by a significant reduction in the arteriovenous oxygen difference measured at submaximal exercise. Systemic oxygen consumption, however, was unaffected at this level of exercise suggesting that the regional perfusion of working skeletal muscle did not rise appreciably in response to treatment. It must be recognised that our data provide no information on oxygen consumption at the substantially higher level of peak exercise which was achieved during felodipine treatment. Despite this the findings bear some similarity to those reported with other vasodilators23 24 26 and indicate that the drug induced rise in cardiac output at submaximal exercise may be directed principally to the cutaneous and visceral circulations rather than to skeletal muscle. Flow redistribution of this type has been reported during treat-319 ment with glyceryl trinitrate in the exercising rat. 30 The sensitivity of systemic oxygen consumption as a measure of regional skeletal muscle flow is uncertain, but it is conceivable that local metabolic factors produce maximal dilatation of muscular arterioles during exercise such that pharmacological intervention is relatively more active elsewhere in the circulation. Thus the principal benefit of felodipine treatment during exercise might relate to attenuation of the rapid rise in left ventricular filling pressure rather than to the increase in cardiac output. Indeed, this might be true of other vasodilators, and recent work has shown that long term treatment with hydralazine-a predominantly arteriolar dilator with little effect on venous tone-is no more effective than placebo in improving exercise tolerance in patients with heart failure. 2 Further support for the primary importance of reduced left ventricular filling pressure as mediator of the beneficial effects of felodipine treatment is provided by the changes in maximal exercise tolerance seen in the present study. Thus the haemodynamic improvement that occurred in response to felodipine was reflected by a considerable increase in maximal exercise capacity, which was sustained throughout the treatment period. Of particular interest, however, was the finding that exercise capacity showed no significant reduction two days after felodipine withdrawal despite a pronounced haemodynamic deterioration. This might, of course, reflect an exercise training effect,3' but the haemodynamic deterioration was manifested principally by a reduction in stroke volume which was not significantly different from control values. Pulmonary capillary wedge pressure, on the other hand, remained appreciably lower than the control value, presumably as a result of residual felodipine activity in the circulation. Thus the sustained improvement in exercise capacity after felodipine withdrawal was likely to have been due, at least in part, to persisting reduction of the left ventricular filling pressure.
Previous investigation has shown beneficial haemodynamic and metabolic responses to acute felodipine treatment in patients with severe congestive heart failure.78 The present study has confirmed that similar effects are sustained during long term treatment and are associated with improvement in exercise tolerance. Felodipine has several advantages over currently available vasodilators and is potentially a useful agent for the long term management of congestive heart failure.
